对比增强CT上的主动脉-病灶衰减差(ALAD):鉴别恶性和良性嗜酸细胞性肿瘤的潜在影像生物标志物
本研究在回顾性队列中评估对比增强CT的主动脉-病灶衰减差(ALAD)能否鉴别恶性与良性嗜酸细胞性肾肿瘤。初始活检数据集79个肾病灶(56个嗜酸细胞瘤,23个嫌色细胞肾细胞癌)中,肾实质期ALAD的AUC为1.00,阈值25.5 HU时敏感度100%、特异度81.5%;验证手术数据集36个病灶(16个嗜酸细胞瘤,20个嫌色细胞肾细胞癌)中AUC为0.93,敏感度100%、特异度87.5%。作者认为肾实质期ALAD在活检组织学不确定时有潜力鉴别良恶性嗜酸细胞性肾肿瘤。
要点
- 肾实质期ALAD在初始活检数据集区分嫌色细胞肾细胞癌与嗜酸细胞瘤的AUC为1.00(95%CI 1.00-1.00)。
- 阈值25.5 HU时初始数据集敏感度100%(82.2%-100%)、特异度81.5%(61.9%-93.7%)。
- 验证手术数据集独立读者测量的AUC为0.93(95%CI 0.84-1.00),敏感度100%(80.0%-100%)、特异度87.5%(60.4%-97.8%)。
核心结论
- 肾实质期ALAD在活检组织学评估不确定时,有潜力在对比增强CT上鉴别良性和恶性嗜酸细胞性肾肿瘤。
研究设计与样本
- 经IRB批准的回顾性研究,纳入初始(活检)数据集和验证(手术)数据集两个独立队列,包含嗜酸细胞瘤和嫌色细胞肾细胞癌。
诊断标准与关键数值
- 肾实质期ALAD在初始活检数据集区分嫌色细胞肾细胞癌与嗜酸细胞瘤的AUC为1.00(95%CI 1.00-1.00),置信区间最窄。
- 阈值25.5 HU时,初始活检数据集敏感度100%(82.2%-100%)、特异度81.5%(61.9%-93.7%)。
- 验证手术数据集由独立读者测量,AUC为0.93(95%CI 0.84-1.00),敏感度100%(80.0%-100%)、特异度87.5%(60.4%-97.8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate whether the Aorta-Lesion-Attenuation-Difference on contrast-enhanced CT can aid in the differentiation of malignant and benign oncocytic renal neoplasms.
MATERIALS AND METHODS: Two independent cohorts-an initial (biopsy) dataset and a validation (surgical) dataset-with oncocytomas and chromophobe renal cell carcinomas (chRCC) were included in this IRB-approved retrospective study. A region of interest was placed on the renal mass and abdominal aorta on the same CT image slice to calculate an Aorta-Lesion-Attenuation-Difference (ALAD). ROC curves were plotted for different enhancement phases, and diagnostic performance of ALAD for differentiating chRCC from oncocytomas was calculated.
RESULTS: Seventy-nine renal masses (56 oncocytomas, 23 chRCC) were analyzed in the initial (biopsy) dataset. Thirty-six renal masses (16 oncocytomas, 20 chRCC) were reviewed in the validation (surgical) cohort. ALAD showed a statistically significant difference between oncocytomas and chromophobes during the nephrographic phase (p < 0.001), early excretory phase (p < 0.001), and excretory phase (p = 0.029). The area under the ROC curve for the nephrographic phase was 1.00 (95% CI: 1.00-1.00) for the biopsy dataset and showed the narrowest confidence interval. At a threshold value of 25.5 HU, sensitivity was 100 (82.2%-100%) and specificity was 81.5 (61.9%-93.7%). When tested on the validation dataset on measurements made by an independent reader, the AUROC was 0.93 (95% CI: 0.84-1.00) with a sensitivity of 100 (80.0%-100%) and a specificity of 87.5 (60.4%-97.8%).
CONCLUSIONS: Nephrographic phase ALAD has potential to differentiate benign and malignant oncocytic renal neoplasms on contrast-enhanced CT if histologic evaluation on biopsy is indeterminate.
引用
- Dhyani M, Grajo JR, Rodriguez D, et al. Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms. Abdom Radiol (NY). 2017. PMID: 28197683. doi:10.1007/s00261-017-1061-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。